促纤维化因子在肝纤维化发生中的作用研究进展

doi:10.3969/j.issn.1672-5069.2016.04.035

摘要/Abstract

摘要： 肝纤维化是多种病因所致的慢性肝损伤的一种创伤愈合反应,持续的炎症与纤维形成最终导致肝硬化。肝星状细胞（HSC）是肝纤维化的主要生成细胞,肝脏内细胞外基质（ECM）的过度沉积是其主要功能。各种促纤维化因子如血管紧张素-II（AngII）、血小板衍生生长因子（PDGF）、血管内皮生长因子（VEGF）、转化生长因子-β（TGF-β）、瘦素、结缔组织因子等可与HSC表面上相应的受体结合,并激活相应的信号通路,进而导致HSC的激活、增殖,ECM过度沉积,引起肝纤维化形成。因此,了解各种促纤维化因子与肝纤维化的关系,可为抗纤维化的科学研究及临床治疗提供理论依据。

关键词: 肝纤维化, 肝星状细胞, 促纤维化因子

Abstract: Liver fibrosis is a wound-healing process in response to chronic liver injury of variety etiologies,which eventually progress to liver cirrhosis during persistent inflammation and fibrogenesis. The hepatic stellate cells（HSC） are the major cell types in the process of liver fibrosis. Excessive production of the extracellular matrix（ECM） is the most special features of fibrosis. A variety of profibrogenic factors such as angiotensin-II（Ang-II）,platelet-derived growth factor（PDGF）,vascular endothelial growth factor（VEGF）,transforming growth factor-β（TGF-β）,leptin and connective tissue factor binding to the corresponding receptors on the HSC surface Results in activation of the corresponding signaling pathways and the activation and proliferation of HSCs,ECM excessive deposition,and hepatic fibrogenesis. Therefore,understanding the relationship of the various profibrogenic factors and liver fibrosis can provide a theoretical basis for scientific research and clinical anti-fibrotic treatment of liver fibrosis.

Key words: Liver fibrosis, Hepatic stellate cells, Profibrogenic factors

施凤综述, 王农荣审校. 促纤维化因子在肝纤维化发生中的作用研究进展[J]. 实用肝脏病杂志, 2016, 19(4): 505-508.

Shi Feng, Wang Nongrong. Roles of profibrogenic factors in liver fibrosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 505-508.

参考文献

[1] Hernandez-Gea V,Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol,2011,6:425-456.
[2] Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med,2007,131（11）:1728-1734.
[3] Schuppan D,Afdhal NH. Liver cirrhosis. Lancet,2008,371（9615）:838-851.
[4] Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol,2010,7:425-436.
[5] Mann DA,Marra F. Fibrogenic signalling in hepatic stellate cells. J Hepatol,2010,52（6）:949-950.
[6] 汪美凤,平健,成扬. 肝星状细胞主要信号转导通路与肝纤维化的关系. 实用肝脏病杂志,2010,13（6）：466-469.
[7] Bataller R,Schwabe RF,Choi YH,et al. NADPH oxidase signal transduces angiotensin ii in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest,2003,112:1383-1394.
[8] Li X,Meng Y,Wu P,et al. Angiotensin II and Aldosterone stimulating NF-κB and AP-1 activation in hepatic fibrosis of rat. Regul Pept,2007,138 （1）:15-25.
[9] 于继红,陈玉帅,林红,等. 血管紧张素II在大鼠酒精性肝纤维化发病机制中的作用. 世界华人消化杂志,2008,16（31）：3492-3497.
[10] Li S,Wang L,Yan X,et al. Salvianolic acid B attenuates rat hepatic fibrosis via downregulating angiotensin II signaling. Evid Based Complement Alternat Med,2012,2012:160726.
[11] Terui Y,Saito T,Watanabe H,et al. Effect of angiotensin receptorantagonist on liver fibrosis in early stages of chronic hepatitis C. Hepatology,2002,36:1022.
[12] Corey KE,Shah N,Misdraji J,et al. The effect of angiotensin-blocking agents on liver fibrosis in patientswith hepatitis C. Liver Int,2009,29:748-753.
[13] Crawford Y,Kasman I,Zhong C,et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer cell,2009,15:21-34.
[14] 黄艳,黄成,李俊. 肝纤维化病程中Kupffer细胞分泌的细胞因子对肝星状细胞活化增殖、凋亡的调控. 中国药理学通报,2010,26（1）：9-13.
[15] Adachi T,Togashi H,Suzuki A,et al. NAD（P）H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology,2005,41:1272-1281.
[16] Si HF,Lv X,Guo A,et al. Suppressive effect of leflunomide on rat hepaticstellate cell proliferation involves on PDGF-BB-elicited activation of three mitogen-activated protein kinases. Cytokine,2008,42（1）:24-31.
[17] 沈永勤,解新科.舒肝化纤颗粒对肝纤维化大鼠MMP-2和PDGF-BB的影响及意义. 青海医学院院报,2010,3（1）：45-48.
[18] Kong DS,Ma J,Lu Y,et al. Effects of acupuncture intervention on hepatic platelet-derived growth factor signaling pathway in CCl4-induced hepatic fibrosis rats. Zhen Ci Yan Jiu,2012,37（2）:87-92.
[19] Okada H,Honda MCampbell JS,et al. Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res,2012,72（17）:4459-4471.
[20] Hao ZM,Fan XB,Li S,et al. Vaccination with platelet-derived growth factor B kinoids inhibits CCl4-induced hepatic fibrosis in mice. J Pharmacol Exp Ther,2012,342（3）:835-842.
[21] 李骢,周情,姜妙娜,等. 中药肝复康对四氯化碳诱导的肝纤维化大鼠肝组织PI3K/PKB信号通路和PDGFR-β表达的影响. 实用肝脏病杂志,2013,16（4）：323-326.
[22] Liu Y,Lui EL,Friedman SL,et al. PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest,2009,89（2）:209-221.
[23] Novo E,Cannito S,Zamara E,et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J Pathol,2007,170:1942-1953.
[24] Kim JM,Kim HG,Han JM,et al. The herbal formula CGX ameliorates the expression of vascular endothelial growth factor inalcoholic liver fibrosis. J Ethnopharmacol,2013,150（3）:892-900.
[25] Liu Y,Wang Z,Wang J,et al. A histone deacetylase inhibitor,largazole,decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth fact or signaling. Liver Int,2013,33（4）:504-515.
[26] Nakamura I,Zakharia K,Banini BA,et al. Brivanib attenuates hepatic fibrosis in vivo stellate cell activation in vitro by inhibition of FGF,VEGF and PDGF signaling. PLoS One,2014,9（4）:e92273.
[27] Tang LX,He RH,Yang G,et al. Asiatic acid inhibits liver fibrosisby blocking TGF-beta /Smad signaling in vivo and in vitro. PLoS One,2012,7（92）:e31350.
[28] Forbes SJ,Parola M. Liver fibrogenic cells. Best Pract Resclin Gastroenterol,2011,25:207-217.
[29] Cheng JH,She H,Han YP,et al. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Astrointest Liver Physiol,2008,294（1）:G39.
[30] Proell V,Carmona-Cuenca I,Murillo MM,et al. TGF-β dependent regulation of oxygen radicals during transdifferentiation of activated hepatic stellate cells to myofibroblastoid cells. Comp Hepatol,2007,6:1.
[31] Lee SH,Do SI,Kim HS. Hyperoxia accelerates progression of hepatic fibrosis by upregu- lation of transforming growth factor-β expression. World J Gastroenterol,2014,20（11）:3011-3017.
[32] 张宝芳,程明亮,王豫萍,等. 蓝莓对大鼠肝纤维化TGF-β1/Smad信号通路的影响. 传染病信息,2010,23（3）：148-153.
[33] Park SY,Lee JY,Tak WY,et al. Erythropoietin decreases carbon tetrachloride induced hepatic fibrosis by inhibiting transforming growth factor-beta. Chin Med J （Engl）,2012,125（17）:3098-3103.
[34] 喻勤,傅向阳,罗伟生,等. 荔枝核总黄酮对大鼠肝纤维化TGF-β/Smad信号通路的影响. 中国实验方剂学杂志,2013,19（18）：223-227.
[35] Chen BL,Peng J,Li QF,et al. Exogenous bone morpho-genetic protein-7 reduces hepatic fibrosis in Schistosoma japonicum-infected mice via trans-forming growth factor-β/Smad signaling. World J Gastroenterol,2013,19（9）:1405-1415.
[36] Ling H,Roux E,Hempel D,et al. Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One,2013,8（1）:e54499.
[37] Bertolani C,Marra F. The role of adipokines in liver fibrosis. Pathophysiology,2008,15（2）:91-101.
[38] Halaas JL,Gajiwla KS,Maffei M,et al. Weight redueing efforts of the plasma proteine neodebythe obesegene. Science,2005,269:543-546.
[39] Berthou F,Rouch C,Gertler A,et al. Chronic central leptininfusion differently modulates brain and liver insulin signaling.Mol Cell Endocrinol,2011,337（1-2）:89-95.
[40] Liu Q,Li Y,Gan LX. Physiological function of leptin in liverand its pathological role in liver diseases. Modern Medicineand Health,2012,28（6）:876-879.
[41] Li H,Li J,Huang C. Correlative research between leptinand TGF-β1 and the recovery on CCl4 induced hepatic fibrosis in rats. Chin Pharmacol Bull,2011,27（4）:473-477.
[42] Bertolani C,Marra F. Role of adipocytokines in hepatic fibrosis. Curr Pharm Des,2010,16 （17）:1929-1940.
[43] De Minicis S,Seki E,Oesterreicher C,et al. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells. Hepatology,2008,48:2016-2026.
[44] Li J,Si HF,Lü X,et al. Suppressive effects of leflunomideon leptin-induced TIMP -1 production involves on hepatic stellate cell proliferation and apoptosis. Eur J Pharmacol,2008,580（1-2）:63-69.
[45] Wang JQ,Li J,Zou YH,et al. Preventive effects of total flavonoids of Litsea coreana level on hepatic steatosis in rats fed with high fat diet. J Ethnopharmacol,2009,121（1）:54-60.
[46] Tang Y,Zheng S,Chen A. Ligustrazine eliminates leptin’s effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology,2009,150（7）:3011-3031.
[47] Tang Y,Chen A. Curcumin protects hepatic stellate cells against leptin-induced activation in vitro by accumulating intracellular lipids. Endocrinology,2010,151（9）:4168-4245.
[48] Handy JA,Fu PP,Kumar P,et al. Adiponectin inhibits leptin signalling via multiple mechanisms to exert protective effects against hepatic fibrosis. Biochem J,2011,440（3）:385-395.
[49] 王美玲,陆伦根. 肝纤维化治疗研究进展. 实用肝脏病杂志,2013,16（4）：369-371.
[50] 李欣,朱英. 肝纤维化发生相关信号传导通路研究进展. 实用肝脏病杂志,2015,18（1）：101-104.